5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure
H

Evolving Strategies for Enhancing the Impact of Immunotherapy in TNBC: Role of TILs, PD-1/PD-L1 Blockade Mechanisms of Action, Available CPi Monotherapy Options

By 5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure FEATURING Hope Rugo
November 28, 2019
0 Comments
Login to view comments. Click here to Login

Featured Video

17:04
Novartis Oncology

Discussion on Overall Survival Data Across 3 Phase III Trials in HR+…

Feat. G. Hortobagyi

Featured Video

18:15
Novartis Oncology

CDK4/6 Inhibitor in Postmenopausal Patients With HR+/HER2- mBC: Anal…

Feat. G. Hortobagyi

Related Content

AUTOPLAY
16:44
Heather McArthur

Modern Immune Therapy Strategies for Triple-Negative Breast Cancer

17:54
Heather McArthur

Modern Immune Therapy in ER, HR+/HER2-, HER2+ Breast Cancer

07:43
Dana-Farber Cancer Institute

Study of Abemaciclib for Patients with RB-Positive, Triple Negative …

Feat. S. Goel
10:12
Holy Cross 9th Annual Winter Oncology Symposium

Emerging Targets in HER-2 Negative, TNBC and HER-3 Positive Breast C…

Feat. M. Abu-Khalaf
07:58
12th ESO-EONS Masterclass in Oncology Nursing

Triple Negative Disease: Adjuvant Therapy, Hormone Receptor + Diseas…

Feat. O. Pagani
13:36
Baltic and Eurasia Masterclass in Clinical Oncology

Systemic Treatment of TNBC: Staging, BRCAness, Chemotherapy Prognost…

Feat. E. Kharchenko
10:06
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure

NCCN Guidelines Update for TNBC and HER2 Breast Cancer: Immunotherap…

Feat. J. Abraham, W. Gradishar
08:27
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure

Therapeutic Options for Systemic Treatment of TNBC & New Data on…

Feat. D. Hicks
15:23
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure

Q&A on Clinical Data Behind Changing the Guidelines, Her2+ Testi…

Feat. D. Hicks
18:38
Peter Schmid

Immunotherapy in Metastatic Triple Negative Breast Cancer: IMpassion…

07:23
Dana-Farber Cancer Institute

Study of Ribociclib and PDR001 in HR+ Metastatic Breast Cancer

Feat. S. Tolaney
07:40
Dana-Farber Cancer Institute

Study of Carboplatin plus Nivolumab in Metastatic Triple-Negative Br…

Feat. S. Tolaney
09:46
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure

Current Concept of Breast Cancer Vaccines: Study on HER2 Directed Va…

Feat. G. Peoples
07:58
Elisa Krill-Jackson

Immunotherapy for TNBC & PARP Inhibitors for BRCA Mutations

16:09
Ashley Mathews

The Breast Tumor Microenvironment: TILs as Therapeutic Target and Pr…

05:52
Ashley Mathews

PD-L1 Testing in Breast Cancer: What Makes a Breast Cancer Patient E…

14:11
UNC Lineberger Comprehensive Cancer Center

UNC's 2019 ASCO Update on Margetuximab + Chemo vs Trastuzumab v…

Feat. E. Ray
07:09
Sandra Swain

Treatment Options in HER2+ Metastatic Breast Cancer: Immunotherapy, …

14:34
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure

Enhancing the Impact of IO in Metastatic / Locally Advanced TNBC: At…

Feat. H. Rugo
05:41
5th Annual Cleveland Breast Cancer Summit: Collaborating For A Cure

Enhancing the Impact of Immunotherapy in TNBC: IO Therapy Options in…

Feat. H. Rugo